AbbVie is a pharmaceutical company that is a recognized leader in the immunology market, whose drugs play key roles in the treatment of plaque psoriasis ... the treatment of diffuse large B ...

Yescarta (axicabtagene ciloleucel) has been approved as a treatment for adults with relapsed or refractory diffuse large B ... for moderate to severe plaque psoriasis, and Ipsen’s Decapeptyl ...

chronic plaque psoriasis, endometrial cancer, gastric cancer, head and neck squamous cell carcinoma, melanoma, colorectal cancer, triple negative breast cancer, small cell lung cancer, urothelial ...

A consistent safety profile and sustained efficacy were observed in patients with moderate to severe plaque psoriasis.

Roflumilast demonstrated effectiveness and safety in treating psoriasis, with added benefits for patients with comorbidities.

More than 125 million people worldwide suffer from some form of psoriasis. If you’ve struggled with your skin health this ...

One study found that pain was self-reported as a symptom in over 4 in 10 people with plaque psoriasis. For some others, the same immune system that causes plaque on your skin could instead inflame ...

Even though he suffers from psoriasis, Joel Thomas considers himself a lucky man. Psoriasis is a chronic skin disorder that affects over seven and a half million Americans. Many are not as lucky ...

J&J is hoping to show that the peptide drug can be a more patient-friendly alternative to injectable biologics for plaque psoriasis, including drugs working on IL-23, such as J&J's own Tremfya ...

The various types and presentations of psoriasis are outlined below. The commonest form of psoriasis is plaque psoriasis in which patients may have sharply circumscribed, round-oval, or nummular (coin ...